Navigation Links
Kuros Announces Allowance of European Patent for Synthetic Biomaterials
Date:6/19/2011

a number of Kuros’ novel product candidates and strengthening the IP position around these candidates adds significant value."

The now allowed claims cover broadly Kuros` proprietary method for forming biomaterials by nucleophilic addition mechanism starting from functionalized precursor components, such as functionalized PEGs. The claims cover the biomaterial (synthetic matrix), its method of production, kits for delivery and several uses. The allowance of the European application follows the grant of the US applications as patents no. US 7,744,912 and US 7,413,739 which were granted with similar broad claims, as well as the grant of the Canadian (CA 2,359,318), Mexican (MX 276585) and Australian (AU 773 914) applications.

About Kuros

http://www.kuros.ch

Kuros is a biotechnology company that is focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications.

Kuros has two biomaterial technology platforms, one based on fibrin sealants and the other based on its own proprietary synthetic technology that can mimic fibrin in many of its attributes.  These materials can be used alone or in combination with biologically active molecules.

The synthetic technology is tailorable and allows generation of products that are delivered as liquids or gels but polymerise, in or on living tissues, to form materials with different physical properties.  For example, Kuros’ synthetic technology can be utilized to develop products ranging from an elastic degradeable dural sealant to a strong and non-degradeable bone cement.

Kuros’ combination products are designed to mimic the body’s natural healing process. The products consist of fusion proteins of naturally occurring bioactive factors, covalently incorporated into fibrin or synthetic matrices. The incorporation of the biologically active molecul
'/>"/>

SOURCE Kuros Biosurgery AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics Announces Results of Registered Direct Offering
2. K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
3. SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
4. Chiltern Announces Additional Investment in Endpoint
5. ACT Announces First Patients Enrolled in Two Clinical Trials Using Embryonic Stem Cells to Treat Stargardts Disease and Dry Age-Related Macular Degeneration
6. Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program
7. Access Legal Announces Appointment of Nicholas Tubb to Medical Negligence Team
8. Vermillion Announces Joining Russell Microcap® Index
9. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
10. Merriman Capital Announces Sponsorship of Circadian Technologies on OTCQX
11. INVO Bioscience Announces Planned Submission To ANVISA For Brazilian Approval Following Completion of Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Topical BioMedics, Inc., is ... pain end their suffering, restoring hope an quality of ... is only possible because of the innovative cellular biomedicines ... technology a reality. , The company was founded ... Lou Paradise (president, chief of research, and Topricin inventor), ...
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 ... announced that it has entered into a collaboration ... UHN,s Centre for Molecular Design and Preformulations (CMDP) ... The goal of the project is to increase ... proprietary buccal insulin spray product, thereby reducing the ...
(Date:9/22/2014)... Norway (PRWEB) September 22, 2014 ... new parcel and pallet measuring device CNS110 ... eliminates manual data entry, offering greater ease and ... savings that result can significantly enhance productivity—an important ... industries where processing volume equals profits. , ...
(Date:9/21/2014)... 21, 2014 Chemical Sciences play ... such as clean air and safe water, healthy ... products. Chemists, environmentalists, food scientists, educators, and scientists ... in the field of Chemistry for the national ... is one of the fastest emerging Sciences, accelerating ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4ScanTape™ Handheld Dimensioner Increases Processing Volume 2Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3
... Results for Sponsoring BrandsCINCINNATI, May 12 ... of physician office-based patient-education programs, announces another record ... climate, the company continued to experience double-digit growth, ... primary care programs (a digital screen waiting room ...
... May 12 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... BioMarin, will present a company update at the Deutsche Bank ... 19, 2009 at 1:55 p.m. ET. Interested parties may ... the investor section of the BioMarin website, www.BMRN.com ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... has successfully completed patient enrolment in its multi-centre Phase ... REOLYSIN(R) in patients with various sarcomas that have metastasized ... been enrolled in the trial. , "We are extremely ...
Cached Biology Technology:Healthy Advice Networks Achieves Strong Growth Despite Challenging Economy 2BioMarin to Present at the Deutsche Bank Health Care Conference 2Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 2Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 3
(Date:9/22/2014)... 2014) Additive manufacturing (AM), or 3D printing, ... of complex-shaped metal components strong enough for structural ... and distortions, as well as quality standards to ... with the technology. Engineers at the University of ... develop enhanced modeling and simulation (M&S) technology and ...
(Date:9/22/2014)... SHELTON, Conn. , Sept. 22, 2014 ... authentication company focused on the growing mobile commerce market, ... to NASDAQ and the recent funding. ... recently completed an essential round of funding and joined ... as well as expand its other biometric and authentication ...
(Date:9/21/2014)... are set to rise again in 2014 - reaching a ... cent projected rise in burning fossil fuels is revealed by ... by researchers at the Tyndall Centre for Climate Change Research ... Engineering, Mathematics and Physical Sciences at the University of Exeter. ... where world leaders will seek to catalyse action on climate ...
Breaking Biology News(10 mins):Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3
... international research consortium has sequenced the genome of the ... Dec. 26 advance online edition of the journal ... possibilities for breeding tastier, hardier varieties of the berry ... the strawberry parts list," said the consortium,s leader Kevin ...
... COLLEGE PARK, Md. The latest success of Martek ... a decade ago in a plain, brick building on ... and early-stage nurturing from the university,s Maryland Technology Enterprise ... into a major international business. On December ...
... University of Arizona researchers may have found a way ... doses without harming healthy body cells. If successful, ... effective to destroy cancer cells and alleviate the harmful ... The invention by Marek Romanowski, an associate professor of ...
Cached Biology News:Georgia Tech team helps decode newly sequenced strawberry genome 2Georgia Tech team helps decode newly sequenced strawberry genome 3Tech firm joins the 'billion dollar club' -- with university help 2Tech firm joins the 'billion dollar club' -- with university help 3Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 2Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 3Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 4
sPLA2-XII Human, Rabbit Polyconal Antibody Anti-Human sPLA2-XII Antibody was raised in rabbits against Human sPLA2-XII His-Tagged Fusion Protein Antigen: The recombinant human protein sPLA-XII...
Recognizes the ~115 kDa NMDA receptor NR1 subunit in rat cortex tissue extracts....
... Monoclonal Anti-β-Tubulin IV Recognizes an ... sequence of β-tubulin isotype IV. ... isotypes is observed. ascites fluid ... C-terminal sequence of β-tubulin isotype ...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Biology Products: